Geftinat Gefitinib – 250 mg (1 pack / 30 tablets)

At a Glance

Generic Name: Gefitinib

Brand Name: Geftinat

Strength & Pack Size: Geftinat 250 mg tablets – 1 pack / 30 tablets

Dosage Form: Oral film-coated tablets

Therapeutic Class: EGFR tyrosine kinase inhibitor, targeted anticancer therapy

Main Indication: Advanced or metastatic non-small cell lung cancer (NSCLC) with sensitising EGFR mutations

Use in Therapy: First-line or subsequent-line targeted treatment under specialist oncology guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from light and moisture

Product Description

Geftinat 250 mg is a generic gefitinib tablet used as targeted therapy in selected adults with advanced or metastatic
non-small cell lung cancer (NSCLC). Many NSCLC tumours, especially adenocarcinomas, carry activating EGFR mutations that make cancer cells strongly dependent on
EGFR signalling for growth and survival. Geftinat 250 mg gefitinib tablets are designed to inhibit this pathway and help slow disease progression in EGFR-mutation–positive lung cancer
under the supervision of an experienced oncology team.

Each Geftinat tablet contains 250 mg gefitinib, the standard oral dose used in most gefitinib protocols worldwide.
The convenient 1 pack / 30 tablets presentation usually corresponds to about one month of once-daily treatment, allowing patients and caregivers to align
Geftinat orders with monthly clinic visits and imaging. As a generic gefitinib 250 mg product, Geftinat contains the same active ingredient and strength as the originator brand,
while often being more accessible in USD for long-term targeted therapy.

Geftinat 250 mg gefitinib tablets are normally prescribed only after molecular testing has confirmed that the tumour carries a sensitising EGFR mutation.
In some settings, Geftinat gefitinib is used as first-line systemic therapy in EGFR-positive NSCLC; in others it is given after chemotherapy, depending on current guidelines.
Generic Meds Mart does not decide whether you should receive gefitinib; we supply Geftinat 250 mg in the strength and quantity that match your written treatment plan.

Key Uses

Geftinat 250 mg gefitinib tablets are typically used under specialist supervision for:

• Advanced or metastatic non-small cell lung cancer (NSCLC), usually adenocarcinoma, with documented sensitising EGFR mutations
• First-line targeted therapy in EGFR-mutation–positive NSCLC where gefitinib is recommended by national or international guidelines
• Subsequent-line targeted therapy in selected patients whose disease remains suitable for EGFR inhibitor treatment after previous systemic therapy

Your oncologist will decide whether Geftinat 250 mg is appropriate based on mutation status, previous treatments, performance status and co-existing illnesses.

How Gefitinib Works in Chemotherapy

Gefitinib is a targeted anticancer medicine from the class of EGFR tyrosine kinase inhibitors.
Unlike classic cytotoxic chemotherapy, Geftinat gefitinib does not directly damage DNA. Instead, it selectively blocks the intracellular tyrosine kinase activity of the
epidermal growth factor receptor (EGFR), which is a critical driver of growth in many EGFR-mutated tumours.

In EGFR-positive NSCLC, constitutively active EGFR triggers downstream signalling through pathways such as RAS/RAF/MEK/ERK and PI3K/AKT, promoting tumour cell proliferation and survival.
By binding to the ATP-binding site of the EGFR tyrosine kinase, Geftinat 250 mg reduces receptor phosphorylation and interrupts these signals.
This deprives tumour cells of key proliferative and anti-apoptotic stimuli, so they are more likely to slow growth or undergo programmed cell death.

Because EGFR is also expressed in normal skin and gastrointestinal epithelium, gefitinib therapy can lead to characteristic side effects such as rash and diarrhea,
which require regular monitoring and supportive care.

Dosage & Administration

The dose and schedule of Geftinat 250 mg must always follow your oncology team’s instructions and current guidelines.
In many protocols, the usual adult dose is one Geftinat 250 mg tablet taken once daily, but only your treating specialists can confirm the correct regimen and duration.

• Take Geftinat tablets once daily at roughly the same time each day, with a glass of water.
• Swallow Geftinat 250 mg whole; do not crush, split or chew the tablet unless your pharmacist gives specific instructions.
• Follow your clinic’s advice on taking gefitinib with or without food and aim for a consistent daily routine.
• Do not change your daily dose, interrupt therapy or take extra tablets without clear guidance from your oncology team.
• If you miss a dose, follow the written instructions from your treatment centre; do not double the next dose unless your doctor tells you to.

Regular clinic visits, blood tests and imaging help your doctors assess response and decide whether your dose of Geftinat 250 mg gefitinib should continue or be adjusted.

Precautions

Before starting Geftinat 250 mg gefitinib tablets, inform your healthcare team about your full medical history and all prescription medicines, over-the-counter products and herbal supplements you use.
Key precautions include:

• Pre-existing liver disease or abnormal liver function tests
• History of interstitial lung disease, pulmonary fibrosis or chronic lung conditions
• Use of strong CYP3A4 inducers or inhibitors that may alter gefitinib blood levels
• Use of gastric acid–reducing medicines that can affect gefitinib tablet absorption
• Pregnancy or breastfeeding; Geftinat gefitinib is not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use reliable contraception during and for a period after Geftinat 250 mg therapy, as directed by their oncologist.

Gefitinib Side Effects

Common side effects

Common side effects of Geftinat 250 mg gefitinib tablets may include:

• Acne-like skin rash on the face, scalp and upper torso
• Dry skin, itching or mild redness
• Diarrhea or loose stools
• Nausea, occasional vomiting or reduced appetite
• Mild mouth sores or irritation in the mouth or throat
• Fatigue or a general feeling of low energy
• Mild elevations in liver enzymes on blood tests

These effects are often manageable with supportive care, dermatologic treatments and, when necessary, dose interruptions or adjustments as decided by your oncology team.

Serious side effects

Less common but serious side effects of gefitinib require urgent medical attention and may include:

• New or rapidly worsening shortness of breath, cough and fever suggesting interstitial lung disease or severe pneumonitis
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, persistent upper abdominal pain
• Severe or prolonged diarrhea leading to dehydration and dizziness
• Severe skin reactions with blistering, peeling or painful widespread rash
• Sudden chest pain, severe breathlessness or other acute symptoms suggesting cardiovascular or pulmonary complications

If you experience any of these symptoms while taking Geftinat 250 mg, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Geftinat 250 mg gefitinib tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton, protected from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use Geftinat after the expiry date printed on the packaging.

Ask your pharmacist or oncology centre how to safely dispose of unused or expired Geftinat gefitinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart provides safe, structured access to key oncology medicines such as
Geftinat 250 mg gefitinib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a verifiable export record.

When you buy Geftinat online from Generic Meds Mart, you benefit from:

• Original gefitinib 250 mg blisters and cartons from licensed suppliers
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured information about Geftinat gefitinib tablets to support discussions with your oncology team
• Support for ordering, payment and delivery questions

Order Now

Geftinat 250 mg gefitinib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Geftinat online, ensure your oncologist has confirmed an EGFR-mutation–positive tumour, recommended gefitinib as part of your treatment plan and specified the daily dose and expected duration.

Select Geftinat 250 mg (1 pack / 30 tablets), choose the quantity that matches your written plan, add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.

Gefticip Gefitinib – 250 mg (1 pack / 30 tablets)

At a Glance

Generic Name: Gefitinib

Brand Name: Gefticip

Strength & Pack Size: 250 mg tablets – 1 pack / 30 tabs

Dosage Form: Oral film-coated tablets

Therapeutic Class: EGFR tyrosine kinase inhibitor, targeted anticancer therapy

Main Indication: Advanced or metastatic non-small cell lung cancer (NSCLC) with sensitising EGFR mutations

Use in Therapy: First-line or subsequent-line targeted treatment under specialist oncology guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from light and moisture

Product Description

Gefticip 250 mg is a gefitinib tablet used as targeted therapy in selected patients with advanced or metastatic
non-small cell lung cancer (NSCLC). Many NSCLC tumours, especially adenocarcinomas, carry activating
EGFR mutations that make tumour cells depend heavily on EGFR signalling for growth and survival.
Gefticip 250 mg gefitinib tablets are designed to inhibit this pathway and help slow disease progression in EGFR-mutation–positive lung cancer
under the supervision of an experienced oncology team.

Each Gefticip tablet contains 250 mg gefitinib, the standard oral dose used in most gefitinib protocols.
The 1 pack / 30 tablets presentation usually corresponds to about one month of once-daily treatment, making it simple to align
Gefticip orders with monthly visits and imaging. As a generic gefitinib 250 mg product, Gefticip offers the same active ingredient and strength
as originator gefitinib while often being more accessible in USD, which is important when targeted therapy is required for many months.

Gefticip 250 mg gefitinib tablets are normally prescribed only after molecular testing has confirmed that the tumour carries a sensitising EGFR mutation.
In some settings, Gefticip is used as first-line systemic therapy in EGFR-positive NSCLC; in others it may be prescribed after chemotherapy, depending on guidelines.
Generic Meds Mart does not decide whether you should receive gefitinib; we supply Gefticip 250 mg in the pack size and quantity that match your written treatment plan.

Key Uses

Gefticip 250 mg gefitinib tablets are typically used under specialist supervision for:

• Advanced or metastatic non-small cell lung cancer (NSCLC), usually adenocarcinoma, with documented sensitising EGFR mutations
• First-line targeted therapy in EGFR-mutation–positive NSCLC where gefitinib is recommended by current guidelines
• Subsequent-line targeted therapy in selected patients whose disease remains suitable for EGFR inhibitor treatment

Your oncologist will decide whether Gefticip 250 mg is appropriate based on EGFR mutation status, prior therapies and overall clinical status.

How Gefitinib Works in Chemotherapy

Gefitinib is a targeted anticancer medicine from the class of EGFR tyrosine kinase inhibitors.
Unlike classic cytotoxic chemotherapy, Gefticip gefitinib does not directly damage DNA.
Instead, it selectively blocks the intracellular tyrosine kinase activity of the epidermal growth factor receptor (EGFR).

In EGFR-positive NSCLC, constitutively active EGFR triggers downstream signalling through pathways such as RAS/RAF/MEK/ERK and PI3K/AKT,
promoting tumour cell survival and proliferation. By binding to the ATP-binding site of the EGFR tyrosine kinase,
Gefticip 250 mg reduces receptor phosphorylation and interrupts these downstream signals.
This deprives tumour cells of proliferative and anti-apoptotic signals, making them more likely to slow growth or undergo programmed cell death.

Because EGFR is also present in normal tissues, especially skin and gastrointestinal epithelium,
gefitinib therapy can lead to class-typical side effects such as rash and diarrhea, which require regular monitoring and supportive care.

Dosage & Administration

The dose and schedule of Gefticip 250 mg must always be set by your oncology team based on current guidelines and your individual situation.
In many protocols, the usual adult dose is one Gefticip 250 mg tablet taken once daily, but only your treating specialists can confirm the correct regimen.

• Take Gefticip tablets once daily at roughly the same time each day, with a glass of water.
• Swallow Gefticip 250 mg whole; do not crush, split or chew the tablet unless your pharmacist provides specific instructions.
• Follow your clinic’s advice on taking gefitinib with or without food and keep a consistent routine.
• Do not change your daily dose, stop treatment or take extra tablets without clear guidance from your oncology team.
• If you miss a dose, follow written instructions from your treatment centre; do not double the next dose unless your doctor tells you to.

Regular visits, blood tests and imaging help your doctors assess response and decide whether your dose of Gefticip 250 mg gefitinib should continue or be adjusted.

Precautions

Before starting Gefticip 250 mg gefitinib tablets, inform your healthcare team about your full medical history and all medicines, supplements and herbal products you use.
Key precautions include:

• Pre-existing liver disease or abnormal liver function tests
• History of interstitial lung disease, pulmonary fibrosis or chronic lung conditions
• Use of strong CYP3A4 inducers or inhibitors that may alter gefitinib blood levels
• Use of gastric acid–reducing medicines that can affect gefitinib tablet absorption
• Pregnancy or breastfeeding; Gefticip gefitinib is not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use reliable contraception during and for a period after Gefticip 250 mg therapy, as directed by their oncologist.

Gefitinib Side Effects

Common side effects

Common side effects of Gefticip 250 mg gefitinib tablets can include:

• Acne-like skin rash on the face, scalp and upper torso
• Dry skin, itching or mild redness
• Diarrhea or loose stools
• Nausea, occasional vomiting or reduced appetite
• Mild mouth sores or irritation in the mouth or throat
• Fatigue or low energy
• Mild elevations in liver enzymes on blood tests

These effects are often manageable with supportive care, dermatologic treatments and, when necessary, dose adjustments as decided by your oncology team.

Serious side effects

Less common but serious side effects of gefitinib require urgent medical attention and may include:

• New or rapidly worsening shortness of breath, cough and fever suggesting interstitial lung disease or severe pneumonitis
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, persistent upper abdominal pain
• Severe or prolonged diarrhea leading to dehydration
• Severe skin reactions with blistering, peeling or painful widespread rash
• Sudden chest pain, severe breathlessness or other acute symptoms suggesting cardiovascular or pulmonary complications

If you experience any of these symptoms while taking Gefticip 250 mg, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Gefticip 250 mg gefitinib tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton, protected from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use Gefticip after the expiry date printed on the packaging.

Ask your pharmacist how to safely dispose of unused or expired Gefticip gefitinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart provides safe, structured access to key oncology medicines such as
Gefticip 250 mg gefitinib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a reliable export record.

When you buy Gefticip online from Generic Meds Mart, you benefit from:

• Original gefitinib 250 mg blisters and cartons from licensed suppliers
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured information about Gefticip gefitinib tablets to support discussions with your oncology team
• Support for ordering, payment and delivery questions

Order Now

Gefticip 250 mg gefitinib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Gefticip online, ensure your oncologist has confirmed an EGFR-mutation–positive tumour, recommended gefitinib as part of your treatment plan and specified the daily dose and duration.

Select Gefticip 250 mg (1 pack / 30 tablets), choose the quantity that matches your written plan, add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.

Geftib Gefitinib – 250 mg (1 pack / 30 tablets)

At a Glance

Generic Name: Gefitinib

Brand Name: Geftib

Strength & Pack Size: Geftib 250 mg tablets – 1 pack / 30 tablets

Dosage Form: Oral film-coated tablets

Therapeutic Class: EGFR tyrosine kinase inhibitor, targeted anticancer therapy

Main Indication: Advanced or metastatic non-small cell lung cancer (NSCLC) with sensitising EGFR mutations as indicated

Use in Therapy: First-line or subsequent-line targeted treatment under specialist oncology guidance

Prescription Status: Prescription-only oncology medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from light and moisture

Product Description

Geftib 250 mg is a generic gefitinib tablet used as targeted therapy in selected patients with advanced or metastatic
non-small cell lung cancer (NSCLC). Many NSCLC tumours, particularly adenocarcinomas, carry activating EGFR mutations that make tumour cells
highly dependent on EGFR signalling. Geftib gefitinib 250 mg tablets are designed to inhibit this pathway, helping to slow disease progression in
EGFR mutation–positive lung cancer under the care of an experienced oncology team.

Each Geftib tablet contains 250 mg gefitinib, the standard oral dose used in most gefitinib treatment protocols.
The 1 pack / 30 tablets presentation provides approximately one month of once-daily therapy for many patients, making it easy to synchronise
Geftib orders with monthly visits and imaging. As a generic gefitinib 250 mg product, Geftib offers the same active ingredient and strength as originator gefitinib
while often being more accessible in USD, which is important for long-term targeted therapy.

Geftib 250 mg gefitinib tablets are typically used in patients with advanced or metastatic NSCLC whose tumours have been confirmed to carry sensitising EGFR mutations.
In some settings, Geftib gefitinib is prescribed as first-line therapy; in others, it is used after prior systemic treatment, depending on local guidelines.
Generic Meds Mart does not design treatment; we supply Geftib 250 mg in the pack size and quantity your oncologist specifies.

Key Uses

Geftib 250 mg gefitinib tablets are generally used for the following indications under specialist supervision:

• Advanced or metastatic non-small cell lung cancer (NSCLC) with documented sensitising EGFR mutations
• First-line targeted therapy in EGFR mutation–positive NSCLC where gefitinib is recommended by current guidelines
• Subsequent-line targeted therapy in selected patients whose disease remains suitable for EGFR inhibitor treatment

Your oncology team will determine whether Geftib 250 mg is appropriate based on mutation testing, prior treatments, performance status and co-morbidities.

How Gefitinib Works in Chemotherapy

Gefitinib is a targeted anticancer medicine from the class of EGFR tyrosine kinase inhibitors.
Unlike classic cytotoxic chemotherapy, Geftib gefitinib does not directly damage DNA.
Instead, it selectively blocks the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR).

In EGFR mutation–positive NSCLC, constitutively active EGFR triggers downstream signalling through pathways such as RAS/RAF/MEK/ERK and PI3K/AKT, promoting tumour cell survival and proliferation.
By binding to the ATP-binding site of the EGFR tyrosine kinase, Geftib 250 mg reduces receptor phosphorylation and interrupts these downstream signals.
This decreases proliferative and anti-apoptotic signalling, making tumour cells more likely to slow growth or undergo programmed cell death.

Because EGFR is also present in normal tissues, gefitinib therapy can lead to characteristic side effects such as skin rash and diarrhea, which require regular monitoring and supportive care.

Dosage & Administration

The dose and schedule of Geftib 250 mg must always follow your oncologist’s instructions.
In many protocols, the usual adult dose is one Geftib 250 mg tablet taken once daily, but only your treating team can confirm the correct regimen for you.

• Take Geftib tablets once daily at about the same time each day, with a glass of water.
• Swallow Geftib 250 mg whole; do not crush, split or chew the tablet unless your pharmacist provides specific instructions.
• Follow your clinic’s advice on taking gefitinib with or without food and try to be consistent with your routine.
• Do not change your daily dose, stop treatment or take extra tablets without clear guidance from your oncology team.
• If you miss a dose, follow the written instructions from your treatment centre; do not double the next dose unless your doctor specifically tells you to.

Regular clinic visits, blood tests and imaging will help your doctors assess response and decide whether your Geftib 250 mg gefitinib dose should continue or be adjusted.

Precautions

Before starting Geftib 250 mg gefitinib tablets, inform your healthcare team about your full medical history and all medicines, supplements and herbal products you use. Key precautions include:

• Pre-existing liver disease or abnormal liver function tests
• History of interstitial lung disease, chronic lung conditions or unexplained breathlessness
• Concurrent use of strong CYP3A4 inducers or inhibitors that may alter gefitinib levels
• Use of gastric acid–reducing medicines that can affect gefitinib tablet absorption
• Pregnancy or breastfeeding; Geftib gefitinib is not recommended and may harm an unborn baby

Men and women of reproductive potential are usually advised to use reliable contraception during and for a period after Geftib 250 mg therapy, as directed by their oncologist.

Gefitinib Side Effects

Common side effects

Common side effects of Geftib 250 mg gefitinib tablets include:

• Acne-like skin rash on the face and upper body
• Dry skin, itching or mild redness
• Diarrhea or loose stools
• Nausea, occasional vomiting or reduced appetite
• Mild mouth sores or oral irritation
• Fatigue or low energy
• Mild elevations in liver enzymes on blood tests

These effects are often manageable with supportive care, dermatologic treatments and, when necessary, dose adjustments as decided by your oncology team.

Serious side effects

Less common but serious side effects of gefitinib require urgent medical attention and may include:

• New or worsening shortness of breath, cough and fever suggesting interstitial lung disease or severe pneumonitis
• Signs of serious liver injury: yellowing of the skin or eyes, dark urine, pale stools, persistent upper abdominal pain
• Severe or persistent diarrhea leading to dehydration
• Severe skin reactions, blistering or extensive rash
• Sudden chest pain or severe breathlessness

If you experience any of these symptoms while taking Geftib 250 mg, seek emergency medical care immediately and contact your oncology team.

Storage

• Store Geftib 250 mg gefitinib tablets at room temperature, preferably below 25 °C.
• Keep tablets in their original blisters and outer carton, protected from moisture and light.
• Keep all anticancer medicines out of the sight and reach of children and pets.
• Do not use Geftib after the expiry date printed on the packaging.

Ask your pharmacist how to safely dispose of unused or expired Geftib gefitinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart provides safe, structured access to key oncology medicines such as
Geftib 250 mg gefitinib tablets at transparent prices in USD.
We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a reliable export record.

When you buy Geftib online from Generic Meds Mart, you benefit from:

• Original gefitinib 250 mg blisters and cartons from licensed suppliers
• Discreet, plain outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured information about Geftib gefitinib tablets to support discussions with your oncology team
• Support for ordering, payment and delivery questions

Order Now

Geftib 250 mg gefitinib tablets are prescription-only targeted anticancer medicines and must be used strictly under specialist supervision.
Before you order Geftib online, ensure your oncologist has confirmed an EGFR mutation–positive tumour, recommended gefitinib as part of your treatment plan and specified the daily dose and duration.

Select Geftib 250 mg (1 pack / 30 tablets), choose the quantity that matches your written plan, add it to your cart and complete the secure checkout on Generic Meds Mart.
Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions and dose adjustments must remain with your healthcare team.

Celplat 50 mg/50 mL Cisplatin Injection (1 pack / 1 vial)

At a Glance

Generic Name: Cisplatin

Brand Name: Celplat

Strength & Pack Size: 50 mg/50 mL (1 mg/mL) solution; 1 pack / 1 vial

Dosage Form & Route: Sterile solution for IV infusion after dilution (hospital/clinic use)

Therapeutic Class: Platinum-based antineoplastic (alkylating-like chemotherapy)

Primary Indication: Testicular, ovarian, and bladder cancers where cisplatin-based regimens are appropriate

Typical Use in Therapy: Given in cycles, often as part of combination chemotherapy under oncology supervision

Usual Adult Dose: Individualised by protocol and specialist; dosing depends on body surface area, kidney function and regimen

Prescription Status: Prescription-only, administered by healthcare professionals

Storage: Store as directed on the vial/carton; protect from light and keep out of reach of children

Product Description

Celplat 50 mg/50 mL contains cisplatin, a platinum-based anticancer medicine used in multiple solid tumours. This presentation provides 1 pack / 1 vial containing 50 mg of cisplatin in 50 mL solution, designed for dilution and intravenous infusion in a clinic or hospital setting. Cisplatin is not a home-use medicine and should only be used when there is a confirmed diagnosis and a treatment plan created by an oncology team.

Cisplatin is widely used because it can be an effective backbone drug in combination regimens. Depending on local guidelines and your individual case, cisplatin may be part of protocols for testicular cancer, ovarian cancer, and bladder cancer, and it may also be used in certain settings for cervical cancer, head and neck cancers, or lung cancer when a cisplatin-based approach is clinically indicated. The exact regimen, combination partners and cycle timing are defined by your treating oncologist, not by self-selection.

Generic Meds Mart supplies Celplat cisplatin injection in original manufacturer packaging sourced through licensed channels. The carton and vial typically show the brand name, active ingredient, strength/concentration, batch number and expiry date to support verification by hospital pharmacies and infusion centres. Orders are shipped in discreet outer packaging to protect privacy, and delivery options may include tracking where regulations allow. Generic Meds Mart supports access and logistics only; all decisions about cisplatin use, cisplatin dosage and monitoring remain with your treating specialists.

Key Uses

Celplat cisplatin injection is commonly used in testicular cancer combination chemotherapy, including protocols where cisplatin is a key component under specialist supervision. Treatment intent and schedule are determined by your oncology team based on tumour type, stage and response assessment.

Celplat may also be used in ovarian cancer regimens, including combination treatment plans where platinum therapy is appropriate according to local standards and prior therapy history. Your specialist will consider previous exposure to platinum drugs, overall treatment goals and expected tolerability before selecting a cisplatin-based regimen.

In bladder cancer, cisplatin-based chemotherapy is often considered for eligible patients, including in neoadjuvant settings or in advanced disease, depending on kidney function, performance status and other clinical factors. Because cisplatin can be intensive and requires close monitoring, eligibility is individualised and alternatives may be considered when standard cisplatin dosing is not suitable. In some protocols, cisplatin is also used with radiotherapy in cervical cancer or head and neck cancers, but such use must follow specialist guidance and local regulations.

How Cisplatin Works in Chemotherapy

Cisplatin works mainly by forming platinum–DNA adducts inside cells. After administration, cisplatin becomes activated and binds to DNA, creating cross-links within and between DNA strands. These cross-links disrupt DNA replication and transcription, triggering cell-cycle arrest and apoptosis, particularly in rapidly dividing cancer cells.

Because cisplatin affects fundamental DNA processes, it can be active across multiple tumour types, especially when combined with other anticancer agents that damage cells through complementary mechanisms. The same DNA-damaging activity can also affect healthy tissues, which is why oncology teams use supportive care, careful dosing and monitoring to reduce risks while maintaining treatment effectiveness.

Dosage & Administration

Celplat cisplatin injection is administered only by healthcare professionals. The vial is typically diluted into an appropriate infusion fluid and given intravenously over a time period specified by the protocol. Dosing is individualised and may be calculated by body surface area, kidney function, blood counts and the specific combination regimen being used. Treatment is usually delivered in cycles with rest periods between cycles, and dose adjustments may be required based on side effects and laboratory results.

Hydration and electrolyte management are important parts of cisplatin administration because kidney toxicity is a key risk. Many protocols include pre- and post-infusion IV fluids and may include magnesium or potassium supplementation. Antiemetic medicines are usually given to reduce nausea and vomiting. Never self-adjust a cisplatin regimen and do not attempt to use this medicine outside a clinic setting. If an infusion is delayed or a cycle is missed, your oncology team will decide how to adjust the schedule safely.

Precautions

Cisplatin can cause significant kidney toxicity, so kidney function tests are routinely monitored before and during therapy. Patients with reduced kidney function may not be eligible for standard cisplatin dosing, and alternatives may be considered by the oncologist. Cisplatin can also cause severe nausea and vomiting without appropriate prevention, so antiemetic plans are essential.

Blood counts may drop during therapy, increasing the risk of infections and bleeding. Report fever, chills, sore throat, easy bruising or unusual bleeding promptly. Cisplatin may cause peripheral neuropathy and hearing-related effects such as tinnitus or hearing loss, which can be cumulative. Tell your team about numbness, tingling, balance changes, ringing in the ears or any hearing changes as early reporting helps clinicians assess risk and adjust treatment when needed.

Electrolyte disturbances such as low magnesium or potassium can occur and may require replacement. Infusion-site reactions and tissue injury can occur if cisplatin leaks outside the vein, so infusions should be administered with appropriate IV access and close observation. Cisplatin is harmful in pregnancy and can affect fertility; discuss contraception and fertility planning with your specialist before treatment. Always share a complete list of medicines and supplements with your oncology team, especially drugs that may affect kidneys or hearing, so overlapping toxicities and interactions can be managed.

Cisplatin Side Effects

Common side effects

Common cisplatin side effects include nausea and vomiting, loss of appetite, fatigue, taste changes and temporary changes in blood counts. Some patients experience constipation or diarrhoea, mouth soreness and transient changes in kidney tests monitored by the clinic. Tingling in the hands or feet, mild numbness or ringing in the ears can occur, especially as cumulative doses increase. Injection-site discomfort may occur during infusion and should be reported to staff.

Serious side effects

Serious side effects require urgent medical attention and may include significant reduction in kidney function, decreased urine output, swelling or severe electrolyte abnormalities. Severe infections due to low white blood cells, uncontrolled bleeding due to low platelets or severe anaemia can occur and may require hospital care. Hearing loss, persistent or worsening neuropathy, severe allergic or infusion reactions and severe uncontrolled vomiting or dehydration are also serious concerns. If you develop high fever, severe shortness of breath, chest pain, confusion, fainting, heavy bleeding, black stools, rapidly worsening weakness or markedly reduced urination, seek urgent care and tell clinicians you are receiving cisplatin.

Storage

Celplat cisplatin vials should be stored according to the instructions printed on the vial and carton, protected from light and kept in the original packaging until use. Storage, dilution and handling are typically managed by hospital pharmacy services following cytotoxic safety procedures. Do not use the product after the expiry date, and ensure unused medicine or materials are disposed of as hazardous pharmaceutical waste according to local regulations. Patients are not usually expected to store cisplatin at home; if transport is required, follow the clinic’s written instructions.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for oncology medicines such as Celplat cisplatin injection. We supply products in original packaging from licensed sources with batch and expiry information visible for verification by pharmacies and clinics. Pricing is shown in USD, and orders can be placed through secure checkout.

Where regulations allow, shipments are sent in discreet outer packaging with tracking options to help coordinate delivery with chemotherapy schedules and appointments. Generic Meds Mart does not provide individual medical advice or determine chemotherapy regimens. Decisions about whether cisplatin is appropriate, the correct dose and how to manage side effects must be made by your treating oncology team.

Order Now

Before you buy Celplat 50 mg/50 mL cisplatin injection online from Generic Meds Mart, make sure your oncologist has confirmed that a cisplatin-based regimen is appropriate and has specified the required dose, cycle schedule and monitoring plan. Your clinic will also confirm kidney function, blood counts, hydration strategy and supportive medicines such as antiemetics before each cycle.

Once your treatment plan is confirmed, select Celplat 50 mg/50 mL (1 pack / 1 vial), choose the quantity needed for the planned cycles and complete secure checkout in USD. Orders are supplied in original packaging with discreet delivery options where permitted, but do not attempt to administer cisplatin yourself or modify the schedule without specialist guidance. For questions about cisplatin dosage, cisplatin side effects or missed cycles, contact your treating oncology team.

FAQ about Celplat (Cisplatin)

Q1: What is Celplat 50 mg/50 mL used for?

Celplat contains cisplatin, a platinum-based chemotherapy medicine used in several solid tumours. It is commonly included in regimens for testicular, ovarian and bladder cancers when prescribed by an oncologist.

Q2: Is Celplat given as a quick injection or an infusion?

Celplat is typically diluted and given by intravenous infusion under clinical supervision. The infusion time and dilution method depend on the protocol used by your oncology team.

Q3: Why are hydration and blood tests important with cisplatin?

Hydration helps reduce kidney toxicity risk, and blood tests monitor kidney function, electrolytes and blood counts. These checks help clinicians adjust treatment and manage side effects safely.

Q4: What should I do if I feel tingling or notice hearing changes?

Tell your oncology team promptly if you develop numbness, tingling, ringing in the ears or hearing changes. These symptoms may indicate cisplatin-related nerve or hearing effects that require assessment.

Q5: Can I take other medicines during cisplatin treatment?

Many patients take supportive medicines during treatment, but interactions and overlapping toxicities are important. Provide your oncologist and pharmacist with a full list of medicines and supplements so they can advise what is safe with your regimen.